Morgan Stanley analyst Judah Frommer maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) yesterday and set a price target of $36.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Judah Frommer’s rating is based on the promising clinical progress of Bicara Therapeutics’ lead candidate, ficerafusp alfa. The company has shown encouraging results in their studies, particularly in the treatment of head and neck squamous cell carcinoma (HNSCC), with upcoming data expected to further demonstrate the drug’s efficacy and durability. The anticipation of updated survival and response data at the upcoming ASCO conference adds to the positive outlook.
Additionally, Bicara is advancing its programs in other HNSCC populations and solid tumors, with ongoing and planned clinical trials exploring various dosing regimens. The company’s strategic focus on expanding its clinical pipeline and the potential for significant developments in their studies contribute to the Buy rating. Furthermore, the company’s financial position, with a cash runway extending into the first half of 2029, supports its ability to continue its research and development efforts.